Literature DB >> 12866196

Temporal profiles of cerebrospinal fluid leukotrienes, brain edema and inflammatory response following experimental brain injury.

Martin U Schuhmann1, Maryam Mokhtarzadeh, Dirk O Stichtenoth, Marco Skardelly, Petra M Klinge, Frank M Gutzki, Madjid Samii, Thomas Brinker.   

Abstract

The post-traumatic changes of leukotrienes LTC4, LTD4, LTE4, and LTB4 in cerebrospinal fluid of rats from 10 min to 7 days were investigated after controlled cortical impact in relation to brain edema and cellular inflammatory response. LTC4 increased five-fold at 4 h, normalized at 24 h, and showed another four-fold increase at 7 days. The same pattern was observed for LTD4 and LTE4. LTB4 however, behaved differently: concentrations were lower and levels peaked two-fold at 24 h. Edema in the injured hemisphere increased continuously up to 24 h without change contralaterally. Leukocyte infiltration, macrophage presence and microglia activation were most prominent at 24 h, 7 days and 24 h respectively. Leukotriene changes in CSF seem to reflect those in the affected tissue, with a time delay and in lower concentrations, and were not linearly correlated to brain edema. The initially high leukotriene levels are rather likely to contribute to the cytotoxic edema than to enhance a vasogenic edema component. The profile of LTB4 was parallel to the time course of leukocyte infiltration, indicating initiation of infiltration as well as prolonged production by leukocytes themselves. The second leukotriene peak at 7 days is likely to follow a different pathway and might be related to a production in macrophages or activated glia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12866196     DOI: 10.1179/016164103101201896

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  13 in total

1.  Blocking leukotriene synthesis attenuates the pathophysiology of traumatic brain injury and associated cognitive deficits.

Authors:  Chelsea E Corser-Jensen; Dayton J Goodell; Ronald K Freund; Predrag Serbedzija; Robert C Murphy; Santiago E Farias; Mark L Dell'Acqua; Lauren C Frey; Natalie Serkova; Kim A Heidenreich
Journal:  Exp Neurol       Date:  2014-03-25       Impact factor: 5.330

2.  Injury-related production of cysteinyl leukotrienes contributes to brain damage following experimental traumatic brain injury.

Authors:  Santiago Farias; Lauren C Frey; Robert C Murphy; Kim A Heidenreich
Journal:  J Neurotrauma       Date:  2009-11       Impact factor: 5.269

3.  Carvacrol together with TRPC1 elimination improve functional recovery after traumatic brain injury in mice.

Authors:  Maximilian Peters; Victoria Trembovler; Alexander Alexandrovich; Moshe Parnas; Lutz Birnbaumer; Baruch Minke; Esther Shohami
Journal:  J Neurotrauma       Date:  2012-11-16       Impact factor: 5.269

Review 4.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.

Authors:  Amaly Nokkari; Hadi Abou-El-Hassan; Yehia Mechref; Stefania Mondello; Mark S Kindy; Ayad A Jaffa; Firas Kobeissy
Journal:  Prog Neurobiol       Date:  2018-01-31       Impact factor: 11.685

5.  Experimental traumatic brain injury.

Authors:  Christiane Albert-Weissenberger; Anna-Leena Sirén
Journal:  Exp Transl Stroke Med       Date:  2010-08-13

Review 6.  Protein biomarkers of epileptogenicity after traumatic brain injury.

Authors:  Denes V Agoston; Alaa Kamnaksh
Journal:  Neurobiol Dis       Date:  2018-07-17       Impact factor: 5.996

7.  CYP4Fs expression in rat brain correlates with changes in LTB4 levels after traumatic brain injury.

Authors:  Ying Wang; Jing Zhao; Auinash Kalsotra; Cheri M Turman; Raymond J Grill; Pramod K Dash; Henry W Strobel
Journal:  J Neurotrauma       Date:  2008-10       Impact factor: 5.269

8.  Multiple mechanisms underlying neuroprotection by secretory phospholipase A2 preconditioning in a surgically induced brain injury rat model.

Authors:  Yuechun Wang; Prativa Sherchan; Lei Huang; Onat Akyol; Devin W McBride; John H Zhang
Journal:  Exp Neurol       Date:  2017-10-24       Impact factor: 5.330

9.  Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.

Authors:  Dawn Eggert; Prasanta K Dash; Nawal Serradji; Chang-Zhi Dong; Pascal Clayette; Francoise Heymans; Huanyu Dou; Santhi Gorantla; Harris A Gelbard; Larisa Poluektova; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2009-06-21       Impact factor: 3.478

10.  Lipid mediators in plasma of autism spectrum disorders.

Authors:  Afaf El-Ansary; Laila Al-Ayadhi
Journal:  Lipids Health Dis       Date:  2012-11-21       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.